Genesis Global Group
PharmOptima
GD3

You will now be redirected to the GD3 website

PharmOptima is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.

Learn more about GD3
Search

Publications

  • 2023

    Somasundaram P, Farley MM, Rudy MA, Stefanoff DG, Shah M, Goli P, Heo J, Wang S, Tran NM, Watkins TA. 2023. Coordinated stimulation of axon regenerative and neurodegenerative transcriptional programs by Atf4 following optic nerve injury. eLife [Preprint].:2023.03.29.534798. doi: 10.1101/2023.03.29.534798 PMID: 37034690

  • 2022

    Zaworski PG, Schwartz R, Burr J, Skutnik D, Mollin A, Kumar B, Ngumah Q, Welch E, Johnson B, Narasimhan J, Weetall M. 2022. Quantitation of Pax-6 protein in ocular impression cytology samples using an electrochemiluminescence immunoassay. Anal Biochem 1;656:114876. Epub 2022 Sep 2. PMID: 36058293

  • 2021

    Maillet E, Skutnik D, Jamison JA, Bailey D, Bacellar-Galdino M, & Garlick D. 2021. 2021. Anti-Inflammatory and Protective Effects of Topical Opthlamic (R)-DOI 0.01% in Allergic Conjunctivitis and Recurrent Intermediate Uveitis Disease Models in Rabbits. IOVS June 2021. 62, 232.

  • 2020

    Christiano R. R. Alves PhD1, Ren Zhang MPH1, Alec J. Johnstone BS1, Reid Garner BS1, Eric J. Eichelberger BS1, Salomé Da Silva Duarte Lepez BA1, Vivian Yi BS1, Victoria Stevens B.S.1, Rebekah Poxson BA2, Rachel Schwartz BA2, Phillip Zaworski MS2, Kathryn J. Swoboda. 2020. MD1 Whole blood survival motor neuron protein levels correlate with severity of denervation in spinal muscular atrophy Muscle and Nerve DOI: 10.1002/mus.26995 2020 In Press

  • 2019

    Ramos DM, d'Ydewalle C, Gabbeta V, Dakka A, Klein SK, Norris DA, Matson J, Taylor SJ, Zaworski PG, Prior TW, Snyder PJ, Valdivia D, Hatem CL, Waters I, Gupte N, Swoboda KJ, Rigo F, Bennett CF, Naryshkin N, Paushkin S, Crawford TO, Sumner CJ. 2019. Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment. Clin Invest https://doi.org/10.1172/JCI124120. [Epub ahead of print] PMID: 31589162

  • 2018

    Strathmann EA, Peters M, Hosseinibarkooie S, Rigo FW, Bennett CF, Zaworski PG, Chen KS, Nothnagel M. 2018. Wirth B. Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice. PLoS One. 2018 Sep 6;13(9):e0203398. doi: 10.1371/journal.pone.0203398. eCollection

    Iyer CC, Corlett KM, Massoni-Laporte A, Duque SI, Madabusi N, Tisdale S, McGovern VL, Le TT, Zaworski PG, Arnold WD, Pellizzoni L, Burghes. 2018. Mild SMN missense alleles are only functional in the presence of SMN2 in mammals. AHM.Hum Mol Genet. 2018 Oct 1;27(19):3404-3416. doi: 10.1093/hmg/ddy251 PMID: 29982416

    Decker DE, Skutnik D, Burr J, Pattison C, Cooley-Themm C, Linn DM, & Linn CL. 2018. 2018. GDF-15 Levels increase in Aqueous Humor Following Hypertonic Saline Injection into the Episcleral Vein in a Rat Claucoma Model. IOVS July 2018. 59, 3504.

  • 2017

    Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Cudkowicz ME, McGovern MM, McNeil DE, Finkel R, Iannaccone ST, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes AHM, Bartlett A, Kissel JT. 2017. NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017 Dec;82(6):883-891. doi: 10.1002/ana.25101. Epub 2017 Dec 8. Free PMC article. Clinical Trial.

  • 2016

    Zaworski P, von Herrmann KM, Taylor S, Sunshine SS, McCarthy K, Risher N, Newcomb T, Weetall M, Prior TW, Swoboda KJ, Chen KS, Paushkin S. 2016. SMN Protein Can Be Reliably Measured in Whole Blood with an Electrochemiluminescence (ECL) Immunoassay: Implications for Clinical Trials PLoS ONE 11(3): e0150640. PMID: 26953792

    Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Iannaccone ST, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Cudkowicz ME, McGovern MM, McNeil DE, Finkel R, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes AHM, Bartlett A, Kissel JT, and the NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators. 2016. Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study. Ann Clin Transl Neurol 3(2): 132-145. PMID: 26900585

    Kolb, SJ, Coffey, CS, Yankey, JW et al. 2016. Baseline results of the NeuroNext spinal muscular atrophy infant biomarker study. Annals of Clinical and Translational Neurology, 21 January 2016;1-14

    Arnold WD, Duque S, Iyer CC, Zaworski P, McGovern VL, Taylor SJ, von Herrmann KM, Kobayashi DT, Chen KS, Kolb SJ, Paushkin SV, Burghes AH. 2016. Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration. PLoS One. 2016 Dec 1;11(12):e0167077. doi: 10.1371/journal.pone.0167077. eCollection 2016. PMID: 27907033

  • 2015

    Czech C, Tang W, Bugawan T, Mano C, Horn C, Iglesias VA, Fröhner S, Zaworski PG, Paushkin S, Chen K, Kremer T. 2015. Biomarker for Spinal Muscular Atrophy: Expression of SMN in Peripheral Blood of SMA Patients and Healthy Controls. PLoS One 10(10): e0139950. PMID: 26468953

    Iyer, CC, McGovern, VL, Murray, JD, Gombash, SE, Zaworski, PG, Foust, KD, Janssen, PM and Burghes, AH. 2015. Low levels of survival motor neuron protein are sufficient for normal muscle function in the SMNdelta7 mouse model of SMA. Hum Mol Genet 2015;24(21):6160-73 PMID: 26276812

    McGovern, VL, Iyer, CC, Arnold, WD, Gombash, SE, Zaworski, PG, Blatnik, AJ, Foust, KD and Burghes, AH. 2015. SMN expression is required in motor neurons to rescue electrophysiological deficits in the SMNdelta7 mouse model of SMA. Hum Mol Genet 2015; 24(19):5524-41 PMID: 26206889

  • 2014

    Li J, Geisbush TR, Arnold WD, Rosen GD, Zaworski PG, Rutkove SB. 2014. A Comparison of Three Electrophysiological Methods for the Assessment of Disease Status in a Mild Spinal Muscular Atrophy Mouse Model. PLoS One 9(10): e111428.

    Cherry JJ, Kobayashi DT, Lynes MM, Naryshkin NN, Tiziano FD, Zaworski PG, Rubin LL, Jarecki J. 2014. Assays for the Identification and Prioritization of Drug Candidates for Spinal Muscular Atrophy. Assay Drug Dev Technol 12(6): 315-341. PMID: 25147906

  • 2012

    Kobayashi DT, Decker D, Zaworski P, Klott K, McGonigal J, Ghazal N, Sly L, Chung B, Vanderlugt J, Chen KS. 2012. Evaluation of peripheral blood mononuclear cell processing and analysis for Survival Motor Neuron protein. PLoS One. 2012;7(11):e50763 PMID: 23226377

  • 2010

    Ho SB, Luu Y, Shekels LL, Batra SK, Kandarian B, Evans DB, Zaworski PG, Wolfe CL, Heinrikson RL. 2010. Activity of recombinant cysteine-rich domain proteins derived from the membrane-bound MUC17/Muc3 family mucins. Biochim Biophys Acta 1800(7):629-38. Epub 2010 Mar 20. PMID: 20332014